Clinical Trial - NCT03107780

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Recruiting

Sponsor: National Cancer Institute (NCI)

Collaborators:

Information provided by (Responsible party): Sponsor

ClinicalTrials.gov Identifier: NCT03107780

Protocol Info

Short Description: Phase 0/I AMG 232 +/- Radiation in GBM
Long Description: Phase 0/I study of AMG 232 concentrations in brain tissue in patients with recurrent glioblastoma and of AMG 232 in combination with radiation in patients with newly diagnosed glioblastoma and unmethylated MGMT promoter
MGH Status: Open
Sponsor: NCI
Disease Program: Brain/CNS

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.




Purpose

This phase I trial studies the side effects and best dose of MDM2 inhibitor KRT-232 in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). MDM2 inhibitor KRT-232 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Condition Title Intervention Phase
Glioblastoma Gliosarcoma Recurrent Glioblastoma Laboratory Biomarker Analysis MDM2 Inhibitor KRT-232 Pharmacological Study Radiation Therapy Phase 1
Study Type Interventional
Official Title Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters

Primary Outcome Measures

Pharmacokinetics (PK) parameters with target inter-tumor drug concentration at >= 25 nm (Part 1) [Time Frame: Up to 3 years] [Designated as safety issue: ]

Maximum tolerated dose (MTD) of MDM2 inhibitor AMG 232 (KRT-232) when combined with concomitant radiation therapy (Part 2) [Time Frame: Up to 16 weeks] [Designated as safety issue: ]


Secondary Outcome Measures

Incidence of adverse events (Part 1) [Time Frame: Up to 30 days following the last dose of study drug] [Designated as safety issue: ]

Variability of MDM2 inhibitor AMG 232 (KRT-232) concentration in tumor enhancing versus (vs.) infiltrative tissue (Part 1) [Time Frame: Up to 3 years] [Designated as safety issue: ]

p21 elevation in tissue (Part 1) [Time Frame: Up to 3 years] [Designated as safety issue: ]

Incidence of adverse events (Part 2) [Time Frame: Up to 10 weeks] [Designated as safety issue: ]

MIC-1 elevation in serum (Part 2) [Time Frame: Up to 3 years] [Designated as safety issue: ]

MDM2 inhibitor AMG 232 (KRT-232) exposure (Part 2) [Time Frame: Up to 3 years] [Designated as safety issue: ]

Estimated Enrollment: 86
Study Start Date: February 2018
Estimated Study Completion Date: December 2021
Estimated Primary Completion Date: December 2021
Arms Assigned Interventions

Experimental:Treatment (MDM2 inhibitor AMG 232 [KRT-232])

PART I: Patients with recurrent glioblastoma receive MDM2 inhibitor AMG 232 (KRT-232) PO QD for 2 days. Within 3-6 hours of the last dose, patients undergo standard of care surgery. Upon recovery (within 45 days), patients with TP53 wild-type tumors continue to receive MDM2 inhibitor AMG 232 (KRT-232) PO QD on days 1-7. Cycles repeat every 21 days in absence of disease progression or unacceptable toxicity. PART II: Within 6 weeks of standard of care surgery, patients with newly diagnosed glioblastoma undergo radiation therapy daily during weeks 1-6. Patients also receive MDM2 inhibitor AMG 232 (KRT-232) PO 3 times weekly on days 2, 3, and 5 for 6 weeks or 2 times weekly on days 2 and 4 for 6 weeks during radiation therapy. PART II (EXPANSION COHORT): Patients receive MDM2 inhibitor AMG 232 (KRT-232) PO QD on days 1-7. Cycles repeat every 21 days in absence of disease progression or unacceptable toxicity.
Radiation:Radiation Therapy
Undergo radiation therapy

Eligibility

Ages Eligible for Study: N/A-N/A

Genders Eligible for Study: All

Accepts Healthly Volunteers: No

Inclusion Criteria:

  • Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
  • Absolute neutrophil count >= 1,500/ul
  • Platelets >= 100,000/ul
  • Hemoglobin >= 10 g/dL (transfuse as necessary to raise levels, no transfusions within 7 days of start)
  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN
  • Alkaline phosphatase < 2.0 x ULN
  • Creatinine =< institutional ULN
  • Creatinine clearance >= 60 ml/min/1.73 m^2 for patients with creatinine levels above institutional normal
  • Activated partial thromboplastin time (APTT)/partial thromboplastin time (PTT) =< 1.5 x institutional ULN
  • Corrected QT interval (QTc) =< 470 msec (based on average of screening triplicates)
  • Patients must be able to provide written informed consent
  • Patients must have magnetic resonance imaging (MRI) within 21 days of starting treatment; patients must be able to tolerate MRI with gadolinium
  • Patients must be maintained on a stable corticosteroid regimen (no increase for 5 days) prior to the baseline MRI
  • Women of childbearing potential must have a negative serum pregnancy test prior to study entry; women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation through 5 weeks (women) after receiving the last dose of AMG 232 (KRT 232); should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of AMG 232 (KRT 232) administration; adequate methods of effective birth control include sexual abstinence (men, women); vasectomy; or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or intrauterine device (IUD) (women); bilateral tubal ligation (women)
  • Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >= five years
  • Patients must be able to swallow oral medications
  • PART 1 PATIENTS (SURGICALLY ELIGIBLE RECURRENT GBM)
  • Part 1 patients must have prior histologically proven glioblastoma that is progressive or recurrent following radiation therapy +/- chemotherapy
  • Part 1 patients must be undergoing repeat surgery that is clinically indicated as determined by their care providers
  • Part 1 patients must have a tumor tissue form indicating availability of archived tissue from initial resection at diagnosis of glioblastoma completed and signed by a pathologist
  • Part 1 patients may have an unlimited number of prior therapy regimens
  • Part 1 patients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:
  • 12 weeks from the completion of radiation
  • 6 weeks from a nitrosourea chemotherapy or mitomycin C
  • 3 weeks from a non-nitrosourea chemotherapy
  • 4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents
  • 2 weeks from administration of a non-cytotoxic, FDA-approved agent, except bevacizumab/ vascular endothelial growth factor receptor (VEGFR) inhibitors (e.g., erlotinib, hydroxychloroquine, etc.)
  • 6 weeks from bevacizumab/VEGFR inhibitors
  • PART 2 PATIENTS (NEWLY DIAGNOSED GBM)
  • Part 2 patients must have histologically confirmed glioblastoma or gliosarcoma
  • Part 2 patients must have recovered from the immediate post-operative period
  • Part 2 patients must have tumor MGMT methylation status of unmethylated; results of routinely used methods for MGMT methylation testing (e.g. mutagenically separated polymerase chain reaction [MSPCR] or quantitative polymerase chain reaction [PCR]) are acceptable
  • Part 2 patient must show evidence of wild-type (WT) p53 status on somatic tissue specimens as assessed by deoxyribonucleic acid (DNA) sequencing
  • Part 2 patients must not have received prior radiation therapy, chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, tumor infiltrating lymphocytes [TIL], lymphokine-activated killer [LAK] or gene therapy), or hormonal therapy for their brain tumor; glucocorticoid therapy is allowed

Exclusion Criteria:

  • Patients receiving any other investigational agents are ineligible
  • Part 1 patients who have not recovered to < Common Terminology Criteria for Adverse Events (CTCAE) grade 2 toxicities related to prior therapy are ineligible
  • Patients with a history of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 (KRT 232) are ineligible
  • Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs; patients previously treated with EIAED may be enrolled if they have been off the EIAED for 10 days or more prior to the first dose of AMG 232 (KRT 232)
  • Patients may not use herbal or non-traditional medications while receiving AMG 232 (KRT 232) therapy; all herbal medicines (e.g., St. John's wort), vitamins, and supplements consumed by the subject within the 30 days prior to receiving the first dose of AMG 232 (KRT 232) should be reviewed by the principal investigator
  • Drugs known to be CYP3A4 substrates with narrow therapeutic windows (such as alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, sirolimus, or terfanide) or CYP2C8 substrates are not allowed; patients must be switched to alternative drugs at least 14 days prior to receiving the first dose of AMG 232 (KRT 232); those patients who cannot switch to alternative drugs will be excluded from the study
  • Treatment with medications known to cause QTc interval prolongation within 7 days of study day 1 is not permitted unless approved by the sponsor; use of ondansetron is permitted for treatment of nausea and vomiting
  • Patients may not be on warfarin, factor Xa inhibitors and direct thrombin inhibitors; Note: low molecular weight heparin and prophylactic low dose warfarin are permitted; APTT/PTT must meet the inclusion criteria; subjects taking warfarin must have their international normalized ratio (INR) followed closely
  • Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, are ineligible; patients with active infection requiring IV antibiotics within 2 weeks of study day 1 are excluded; patients with myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association [NYHA] class III and higher), unstable angina, or cardiac arrhythmia requiring medication are excluded
  • Patients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis), are ineligible
  • Patients with history of bleeding diathesis are ineligible
  • Patients with positive hepatitis B surface antigen (HepBsAg), positive hepatitis total core antibody with negative HBsAG, or detectable hepatitis C virus ribonucleic acid (RNA) by a polymerase-chain reaction (PCR) assay are ineligible (screening is generally done by hepatitis C antibody [HepCAb], followed by hepatitis C virus RNA by PCR if HepCAb is positive)
  • Pregnant women are excluded from this study as no studies evaluating the reproductive toxicity of AMG 232 (KRT 232) have been conducted to date; the teratogenic potential of AMG 232 (KRT 232) in laboratory animals, if any, is unknown; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AMG 232 (KRT 232), breastfeeding should be discontinued if the mother is treated with AMG 232 (KRT 232) through 1 week after receiving the last dose of study drug
  • Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AMG 232 (KRT 232); in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
  • Patients with a planned use of Novo-TTF (Optune) are ineligible

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT03107780

Locations

  • United States, Alabama
    • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States, 35233
  • United States, California
    • UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States, 90095
  • United States, Maryland
    • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287
  • United States, Massachusetts
    • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114
    • Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215
  • United States, Michigan
    • Henry Ford Hospital Detroit, Michigan, United States, 48202
  • United States, New York
    • Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065
  • United States, North Carolina
    • Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157
  • United States, Pennsylvania
    • University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104
    • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232

Sponsors and Collaborators

National Cancer Institute (NCI)

More Information

No publications provided

Responsible Party: Sponsor
ClinicalTrials.gov Identifier: NCT03107780
Other Study ID Numbers: NCI-2017-00568
Study First Received:
Last Updated:
Health Authority:

Additional relevant MeSH terms:

Glioblastoma

Gliosarcoma

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.







ClinicalTrials.gov processed this data on September 03, 2020